Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

HIV Infection

Free Subscription Articles published in J Med Virol Retrieve available abstracts of 173 articles: HTML format

Single Articles

April 2024
1. KIM M, Kim E
   Effective vaccination strategies for human papillomavirus (HPV) infection and cervical cancer based on the mathematical model with a stochastic process.
   J Med Virol. 2024;96:e29558.
   PubMed     Abstract available
   
   
   
2. JIANG X, Gao Z, Sharma PP, Kumar S, et al
   Discovery of low-molecular-weight phenylalanine derivatives as novel HIV capsid modulators with improved antiretroviral activity and metabolic stability.
   J Med Virol. 2024;96:e29594.
   PubMed     Abstract available
   
   
   March 2024
3. XIAO J, Luo Y, Li Y, Yao X, et al
   The characteristics of BCR-CDR3 repertoire in COVID-19 patients and SARS-CoV-2 vaccinated volunteers.
   J Med Virol. 2024;96:e29488.
   PubMed     Abstract available
   
   
   
4. XIE M, Wang Z, Zhao F, Li Y, et al
   Structure-based design of diarylpyrimidines and triarylpyrimidines as potent HIV-1 NNRTIs with improved metabolic stability and drug resistance profiles.
   J Med Virol. 2024;96:e29502.
   PubMed     Abstract available
   
   
   
5. CORMA-GOMEZ A, Cabello A, Orviz E, Morante-Ruiz M, et al
   Long or complicated mpox in patients with uncontrolled HIV infection.
   J Med Virol. 2024;96:e29511.
   PubMed     Abstract available
   
   
   
6. WANG Z
   Novel diarylpyrimidine subtypes as HIV-1 nonnucleoside reverse transcriptase inhibitors with improved resistance profile.
   J Med Virol. 2024;96:e29553.
   PubMed    
   
   
   
7. TRUNFIO M, Tang B, Okwuegbuna O, Iudicello JE, et al
   Longitudinal analysis of CSF HIV RNA in untreated people with HIV: Identification of CSF controllers.
   J Med Virol. 2024;96:e29550.
   PubMed     Abstract available
   
   
   
8. FARAONE JN, Wang X, Qu P, Zheng YM, et al
   Neutralizing antibody response to SARS-CoV-2 bivalent mRNA vaccine in SIV-infected rhesus macaques: Enhanced immunity to XBB subvariants by two-dose vaccination.
   J Med Virol. 2024;96:e29520.
   PubMed     Abstract available
   
   
   
9. KASSAM P, El-Zein M, Laurie C, Tota JE, et al
   Use of a carrageenan-based gel had no impact on anal HPVs 16 and 18 viral loads in gay, bisexual, and other men who have sex with men.
   J Med Virol. 2024;96:e29562.
   PubMed     Abstract available
   
   
   February 2024
10. SHMAKOVA A, Hugot C, Kozhevnikova Y, Schwager Karpukhina A, et al
    Chronic HIV-1 Tat action induces HLA-DR downregulation in B cells: A mechanism for lymphoma immune escape in people living with HIV.
    J Med Virol. 2024;96:e29423.
    PubMed     Abstract available
    
    
    
11. LIU W, Li L, Yin M, Cao C, et al
    High-speed centrifugation rather than Lipoclear reagent can be used for removing the interference of lipemia on serological tests of infectious diseases: AIDS, hepatitis B, hepatitis C, and syphilis by chemiluminescent microparticle immunoassay.
    J Med Virol. 2024;96:e29385.
    PubMed     Abstract available
    
    
    
12. ZHAN H, Xie Y, Liu Y, Cheng L, et al
    Omicron BA.4/5 neutralization and cell-mediated immune responses in relation to baseline immune status and breakthrough infection among PLWH: A follow-up cohort study.
    J Med Virol. 2024;96:e29446.
    PubMed     Abstract available
    
    
    
13. CHU J, Zheng R, Chen H, Chen Y, et al
    Dynamic m(6) A profiles reveal the role of YTHDC2-TLR2 signaling axis in Talaromyces marneffei infection.
    J Med Virol. 2024;96:e29466.
    PubMed     Abstract available
    
    
    
14. SERWIN K, Scheibe K, Urbanska A, Aksak-Was B, et al
    Phylodynamic evolution of HIV-1 A6 sub-subtype epidemics in Poland.
    J Med Virol. 2024;96:e29482.
    PubMed     Abstract available
    
    
    
15. DEL PINO M, Vorsters A, Joura EA, Doorbar J, et al
    Risk factors for human papillomavirus infection and disease: A targeted literature summary.
    J Med Virol. 2024;96:e29420.
    PubMed     Abstract available
    
    
    
16. XU Y, Jiao K, Zhang Y, Huang S, et al
    Behavioral intentions of self-isolation and informing close contacts after developing mpox-related symptoms among young men who have sex with men in China.
    J Med Virol. 2024;96:e29470.
    PubMed     Abstract available
    
    
    January 2024
17. SISTERE-ORO M, Du J, Wortmann DDJ, Filippi MD, et al
    Pan-pox-specific T-cell responses in HIV-1-infected individuals after JYNNEOS vaccination.
    J Med Virol. 2024;96:e29317.
    PubMed     Abstract available
    
    
    
18. DURSTENFELD MS, Peluso MJ, Lin F, Peyser ND, et al
    Association of nirmatrelvir for acute SARS-CoV-2 infection with subsequent Long COVID symptoms in an observational cohort study.
    J Med Virol. 2024;96:e29333.
    PubMed     Abstract available
    
    
    
19. LIANG Z, Tong J, Sun Z, Liu S, et al
    Rational prediction of immunogenicity clustering through cross-reactivity analysis of thirteen SARS-CoV-2 variants.
    J Med Virol. 2024;96:e29314.
    PubMed     Abstract available
    
    
    
20. RIZZO A, Moschese D, Salari F, Giacomelli A, et al
    High prevalence of high-risk HPV genotypes in individuals attending an infectious diseases clinic from 2018 to 2022 in Milan, Italy.
    J Med Virol. 2024;96:e29370.
    PubMed     Abstract available
    
    
    
21. WANG Y, Lan X, Qiao Y, Huo Y, et al
    Safety and immunogenicity of homologous prime-boost CoronaVac vaccine in people living with HIV in China: A multicenter prospective cohort study.
    J Med Virol. 2024;96:e29395.
    PubMed     Abstract available
    
    
    
22. GUILLEN-CALVO L, Negredo A, Sanchez-Mora P, Molero P, et al
    Mpox, herpes, and enteroviruses: Differential diagnosis.
    J Med Virol. 2024;96:e29371.
    PubMed    
    
    
    December 2023
23. JENKINS F, Le T, Farhat R, Pinto A, et al
    Validation of an HIV whole genome sequencing method for HIV drug resistance testing in an Australian clinical microbiology laboratory.
    J Med Virol. 2023;95:e29273.
    PubMed     Abstract available
    
    
    
24. RANI AQ, Bonam SR, Zhou J, Li J, et al
    BRD4 as a potential target for human papillomaviruses associated cancer.
    J Med Virol. 2023;95:e29294.
    PubMed     Abstract available
    
    
    
25. VINUELA L, de Salazar A, Fuentes A, Serrano-Conde E, et al
    Transmitted drug resistance to antiretroviral drugs in Spain during the period 2019-2021.
    J Med Virol. 2023;95:e29287.
    PubMed     Abstract available
    
    
    
26. LIU J, Yang R, Huang J, Zhang M, et al
    Prevalence and risk factors of anal human papillomavirus infection among men with anal condyloma acuminata by HIV status in ShenZhen, Southeast China: A retrospective cohort study.
    J Med Virol. 2023;95:e29282.
    PubMed     Abstract available
    
    
    
27. SHISHIDO AA, Street S
    Optimal management of severe mpox in patients with uncontrolled human immunodeficiency virus.
    J Med Virol. 2023;95:e29277.
    PubMed     Abstract available
    
    
    
28. MARGOT N, Naik V, Nekkalapudi A, Boopathy A, et al
    Rapid HIV-1 genotyping assay for the detection of capsid mutations.
    J Med Virol. 2023;95:e29292.
    PubMed     Abstract available
    
    
    
29. ABDEL-SAMIEE M, Youssef MI, Elghamry F, Bazeed M, et al
    A multicentric and nationwide predictive study role of T cell sub-population in the prevalence and prognosis of cryoglobulinemia among genotype 4 chronic hepatitis C patients.
    J Med Virol. 2023;95:e29248.
    PubMed     Abstract available
    
    
    
30. WATANABE D, Iida S, Hirota K, Ueji T, et al
    Evaluation of human herpesvirus-8 viremia and antibody positivity in patients with HIV infection with human herpesvirus-8-related diseases.
    J Med Virol. 2023;95:e29324.
    PubMed     Abstract available
    
    
    
31. DU M, Zheng M, Liu J, Yang G, et al
    The prevalence of mpox and its association with sexual behavior among Chinese men who have sex with men in early August 2023.
    J Med Virol. 2023;95:e29320.
    PubMed     Abstract available
    
    
    
32. LI J, Nie L, Guo C, Deng Y, et al
    Immunogenicity and safety of inactivated SARS-CoV-2 vaccines in people living with HIV: A longitudinal cohort study.
    J Med Virol. 2023;95:e29334.
    PubMed     Abstract available
    
    
    November 2023
33. WANG P, Liu JB, Wang X, Meng FZ, et al
    Activation of Toll-like receptor 3 inhibits HIV infection of human iPSC-derived microglia.
    J Med Virol. 2023;95:e29217.
    PubMed     Abstract available
    
    
    
34. SEPULVEDA-CRESPO D, Jimenez-Sousa MA, Fernandez-Rodiguez A, Munoz-Fernandez MA, et al
    IL7RA rs10491434 polymorphism is related to spontaneous HIV infection control in naive HIV-infected patients: A retrospective study.
    J Med Virol. 2023;95:e29214.
    PubMed     Abstract available
    
    
    
35. AKBARI E, Milani A, Seyedinkhorasani M, Bolhassani A, et al
    HPV co-infections with other pathogens in cancer development: A comprehensive review.
    J Med Virol. 2023;95:e29236.
    PubMed     Abstract available
    
    
    
36. BUCK AM, Deitchman AN, Takahashi S, Lu S, et al
    The breadth of the neutralizing antibody response to original SARS-CoV-2 infection is linked to the presence of Long COVID symptoms.
    J Med Virol. 2023;95:e29216.
    PubMed     Abstract available
    
    
    
37. LIM CK, Romeo O, Tran BM, Flanagan DJ, et al
    Assessment of hepatitis B virus infection and interhost cellular responses using intrahepatic cholangiocyte organoids.
    J Med Virol. 2023;95:e29232.
    PubMed     Abstract available
    
    
    October 2023
38. SHANG W, Cao G, Wu Y, Kang L, et al
    Spatiotemporal cluster of mpox in men who have sex with men: A modeling study in 83 countries.
    J Med Virol. 2023;95:e29166.
    PubMed     Abstract available
    
    
    
39. LAGI F, Giacomelli A, Borghi V, Ciccullo A, et al
    Efficacy and tolerability of dolutegravir/lamivudine versus dolutegravir/rilpivirine in switching from a three-drug regimen based on nonnucleoside reverse transcriptase inhibitors: A retrospective cohort study.
    J Med Virol. 2023;95:e29149.
    PubMed     Abstract available
    
    
    
40. OOMEN PGA, Dijkstra S, Hofstra LM, Nijhuis MM, et al
    Integrated analysis of viral blips, residual viremia, and associated factors in people with HIV: Results from a retrospective cohort study.
    J Med Virol. 2023;95:e29178.
    PubMed     Abstract available
    
    
    
41. KOWALSKI J, Cielniak I, Garbacz-Lagozna E, Cholewinska-Szymanska G, et al
    Comparison of clinical course of Mpox among HIV-negative and HIV-positive patients: A 2022 cohort of hospitalized patients in Central Europe.
    J Med Virol. 2023;95:e29172.
    PubMed     Abstract available
    
    
    
42. FU L, Wang B, Wu K, Yang L, et al
    Epidemiological characteristics, clinical manifestations, and mental health status of human mpox cases: A multicenter cross-sectional study in China.
    J Med Virol. 2023;95:e29198.
    PubMed     Abstract available
    
    
    September 2023
43. PRETET JL, Baraquin A, Barret AS, Bercot B, et al
    Anal and oropharyngeal HPV distribution in HIV-negative multipartner MSM using self-sampling kits for HIV and sexually transmitted infection screening.
    J Med Virol. 2023;95:e29068.
    PubMed     Abstract available
    
    
    
44. MOLINA IS, Jimenez-Vasquez V, Lizarraga W, Sevilla N, et al
    Sub-lineage B.1.6 of hMPXV in a global context: Phylogeny and epidemiology.
    J Med Virol. 2023;95:e29056.
    PubMed     Abstract available
    
    
    
45. DAVIS DA, Shrestha P, Yarchoan R
    Hypoxia and hypoxia-inducible factors in Kaposi sarcoma-associated herpesvirus infection and disease pathogenesis.
    J Med Virol. 2023;95:e29071.
    PubMed     Abstract available
    
    
    
46. CHEN WH, Axell-House DB
    Intravenous tecovirimat treatment of oral monkeypox lesions in a patient with HIV-1.
    J Med Virol. 2023;95:e29078.
    PubMed     Abstract available
    
    
    
47. ZHENG C
    Assessing the prognostic scoring models to predict patient outcomes in AIDS-related diffuse large B-cell lymphoma.
    J Med Virol. 2023;95:e29070.
    PubMed    
    
    
    
48. YAO X, Xu Z, Duan C, Zhang Y, et al
    Role of human papillomavirus and associated viruses in bladder cancer: An updated review.
    J Med Virol. 2023;95:e29088.
    PubMed     Abstract available
    
    
    
49. BRUZZESI E, Gabrieli A, Bernasconi D, Marchetti G, et al
    HIV-DNA decrease during treatment in primary HIV-1 infection with three different drug regimens: Italian Network of Acute HIV Infection (INACTION) clinical trial.
    J Med Virol. 2023;95:e29114.
    PubMed     Abstract available
    
    
    
50. ZIMMERMANN HML, Gultzow T, Marcos TA, Wang H, et al
    Mpox stigma among men who have sex with men in the Netherlands: Underlying beliefs and comparisons across other commonly stigmatized infections.
    J Med Virol. 2023;95:e29091.
    PubMed     Abstract available
    
    
    
51. TIAN T, Fu L, Lu Z, Bian J, et al
    Changes in HPV prevalence, incidence, and clearance following the use of HIV pre-exposure prophylaxis (PrEP) among MSM in Xinjiang, China: An observational cohort study.
    J Med Virol. 2023;95:e29112.
    PubMed     Abstract available
    
    
    August 2023
52. LIM CK, Tran BM, Flanagan D, McCartney E, et al
    Assessment of HBV infection and inter-host cellular responses using intrahepatic cholangiocyte organoids.
    J Med Virol. 2023;95:e28975.
    PubMed     Abstract available
    
    
    
53. LI R, Lin C, Dong S, Li J, et al
    Phylogenetics and phylogeographic characteristics of coxsackievirus A16 in hand foot and mouth disease and herpangina cases collected in Beijing, China from 2019 to 2021.
    J Med Virol. 2023;95:e28991.
    PubMed     Abstract available
    
    
    
54. GIOVANETTI M, Branda F, Cella E, Scarpa F, et al
    Epidemic history and evolution of an emerging threat of international concern, the severe acute respiratory syndrome coronavirus 2.
    J Med Virol. 2023;95:e29012.
    PubMed     Abstract available
    
    
    
55. ADACHI E, Saito M, Kikuchi T, Ikeuchi K, et al
    Incidence of sexually transmitted hepatitis C virus infection among men who have sex with men in Japan from 2009 to 2023.
    J Med Virol. 2023;95:e29039.
    PubMed     Abstract available
    
    
    
56. GUTERRES A
    Viral load: We need a new look at an old problem?
    J Med Virol. 2023;95:e29061.
    PubMed     Abstract available
    
    
    
57. JIAO K, Xu Y, Huang S, Zhang Y, et al
    Mpox risk perception and associated factors among Chinese young men who have sex with men: Results from a large cross-sectional survey.
    J Med Virol. 2023;95:e29057.
    PubMed     Abstract available
    
    
    July 2023
58. HOGAN G, Winer BY, Ahodantin J, Sellau J, et al
    Persistent hepatitis B virus and HIV coinfections in dually humanized mice engrafted with human liver and immune system.
    J Med Virol. 2023;95:e28930.
    PubMed     Abstract available
    
    
    
59. FAZAL H, Gandrakota N, Shackelford J, Kulshreshtha A, et al
    Mpox infection in an AIDS patient with syphilis manifesting with scrotal and penile cellulitis.
    J Med Virol. 2023;95:e28906.
    PubMed    
    
    
    
60. MAHTANI AU, Seelam H, Padda I, Mahmoud M, et al
    Severe soft tissue infection: A complication of mpox in an individual with HIV coinfection requiring vaccinia intravenous immunoglobulin and intravenous tecovirimat.
    J Med Virol. 2023;95:e28917.
    PubMed     Abstract available
    
    
    
61. LARA-AGUILAR V, Crespo-Bermejo C, Llamas-Adan M, Grande-Garcia S, et al
    HCV spontaneous clearers showed low senescence profile in people living with HIV under long ART.
    J Med Virol. 2023;95:e28955.
    PubMed     Abstract available
    
    
    
62. GONG X, Chi H, Xia Z, Yang G, et al
    Advances in HPV-associated tumor management: Therapeutic strategies and emerging insights.
    J Med Virol. 2023;95:e28950.
    PubMed     Abstract available
    
    
    
63. ZHANG J, Zhang Y, Khanal S, Cao D, et al
    Synthetic gRNA/Cas9 ribonucleoprotein targeting HBV DNA inhibits viral replication.
    J Med Virol. 2023;95:e28952.
    PubMed     Abstract available
    
    
    
64. CAI M, Hu Z, Yang Y, Mao T, et al
    Characterization of a human-mouse chimeric monoclonal antibody targeting rabies virus glycoprotein.
    J Med Virol. 2023;95:e28954.
    PubMed     Abstract available
    
    
    
65. LI M, Zhou J, Zhang K, Yuan Y, et al
    Characteristics of genotype, drug resistance, and molecular transmission network among newly diagnosed HIV-1 infections in Shenzhen, China.
    J Med Virol. 2023;95:e28973.
    PubMed     Abstract available
    
    
    June 2023
66. GUO M, Zhu J, Hu Z, Wang Q, et al
    Histone mRNA polyadenylation-mediated inflammation underlies various virus infections and cancers.
    J Med Virol. 2023;95:e28826.
    PubMed     Abstract available
    
    
    
67. SEPULVEDA-CRESPO D, Jimenez-Sousa MA, Fernandez-Rodiguez A, Munoz-Fernandez MA, et al
    IRF5-TNOP3 polymorphisms are associated with elite control of HIV infection: A retrospective study.
    J Med Virol. 2023;95:e28841.
    PubMed     Abstract available
    
    
    
68. PIORKOWSKI G, Ghosn J, Coppee R, Mailhe M, et al
    Genomic diversity of mpox virus in Paris area (France) during the 2022 outbreak.
    J Med Virol. 2023;95:e28853.
    PubMed     Abstract available
    
    
    
69. COLAVITA F, Matusali G, Mazzotta V, Bettini A, et al
    Profiling the acute phase antibody response against mpox virus in patients infected during the 2022 outbreak.
    J Med Virol. 2023;95:e28851.
    PubMed     Abstract available
    
    
    
70. AHMADI AS, Zadheidar S, Sadeghi K, Nejati A, et al
    SARS-CoV-2 intrahost evolution in immunocompromised patients in comparison with immunocompetent populations after treatment.
    J Med Virol. 2023;95:e28877.
    PubMed     Abstract available
    
    
    
71. WAN Z, Zhao J, Xu L, Sun P, et al
    Global and regional estimates of cervical cancer burden associated with human immunodeficiency virus infection from 1990 to 2019.
    J Med Virol. 2023;95:e28891.
    PubMed     Abstract available
    
    
    May 2023
72. ZHAO H, Liu R, Tao Y, Bertero L, et al
    Construction and validation of prognostic scoring models to risk stratify patients with acquired immune deficiency syndrome-related diffuse large B cell lymphoma.
    J Med Virol. 2023;95:e28821.
    PubMed     Abstract available
    
    
    
73. RUECA M, Tucci FG, Mazzotta V, Gramigna G, et al
    Temporal intra-host variability of mpox virus genomes in multiple body tissues.
    J Med Virol. 2023;95:e28791.
    PubMed     Abstract available
    
    
    
74. ZENG G, He F, Zhang X, Li G, et al
    Antibody response to the third dose of inactivated COVID-19 vaccine in people living with HIV (PLWH): A longitudinal cohort.
    J Med Virol. 2023;95:e28797.
    PubMed     Abstract available
    
    
    
75. SEVGI DY, Demirbas ND, Genc Yaman I, Derin O, et al
    Evaluation of the late presentation and associated factors of people living with HIV in Turkey.
    J Med Virol. 2023;95:e28781.
    PubMed     Abstract available
    
    
    
76. XU Q, Dong H, Wang Z, Zhang P, et al
    Integration and viral oncogene expression of human papillomavirus type 16 in oropharyngeal squamous cell carcinoma and gastric cancer.
    J Med Virol. 2023;95:e28761.
    PubMed     Abstract available
    
    
    
77. DAI J, Li F, Yang Y, Tang X, et al
    Serological responses to smallpox A33 antigen and monkeypox A35 antigen in healthy people and people living with HIV-1 from Guangzhou, China.
    J Med Virol. 2023;95:e28763.
    PubMed     Abstract available
    
    
    
78. BROSIUS I, Dijck CV, Coppens J, Vandenhove L, et al
    Presymptomatic viral shedding in high-risk mpox contacts: A prospective cohort study.
    J Med Virol. 2023;95:e28769.
    PubMed     Abstract available
    
    
    
79. DE MENDOZA C, Carrizo P, Sauleda S, Richart A, et al
    The slowdown of new infections by human retroviruses has reached a plateau in Spain.
    J Med Virol. 2023;95:e28779.
    PubMed     Abstract available
    
    
    April 2023
80. COX S, Margot N, Callebaut C
    Antiviral activity of tenofovir alafenamide (TAF) against HIV-1 clinical isolates harboring K65R.
    J Med Virol. 2023;95:e28723.
    PubMed     Abstract available
    
    
    
81. LU T, Chen Z, Cao Y, Ao L, et al
    Dynamic immunogenicity after primary and booster inactivated SARS-CoV-2 vaccination in people living with HIV: A longitudinal observational study.
    J Med Virol. 2023;95:e28730.
    PubMed     Abstract available
    
    
    March 2023
82. SCARPA F, Giovanetti M, Azzena I, Locci C, et al
    Genome-based survey of the SARS-CoV-2 BF.7 variant from Asia.
    J Med Virol. 2023 Mar 31. doi: 10.1002/jmv.28714.
    PubMed     Abstract available
    
    
    
83. SHIN H, Shin H, Rahmati M, Koyanagi A, et al
    Comparison of clinical manifestations in mpox patients living with HIV versus without HIV: a systematic review and meta-analysis.
    J Med Virol. 2023 Mar 29. doi: 10.1002/jmv.28713.
    PubMed     Abstract available
    
    
    
84. TRUNFIO M, Pinnetti C, Arsuffi S, Bai F, et al
    The Presence of Resistance-associated Mutations in Reverse Transcriptase Gene is Associated with Cerebrospinal Fluid HIV-1 Escape: a multicentric retrospective analysis.
    J Med Virol. 2023 Mar 26. doi: 10.1002/jmv.28704.
    PubMed     Abstract available
    
    
    
85. ADEN D, Zaheer S, Kumar R, Ranga S, et al
    Monkeypox (Mpox) outbreak during COVID-19 pandemic - Past and the future.
    J Med Virol. 2023 Mar 23. doi: 10.1002/jmv.28701.
    PubMed     Abstract available
    
    
    
86. GNANAPRAKASAM R, Keller M, Glassman R, El-Khoury M, et al
    Mpox in the New York Metropolitan area, Summer 2022.
    J Med Virol. 2023 Mar 23. doi: 10.1002/jmv.28699.
    PubMed     Abstract available
    
    
    
87. ZHAO H, Feng A, Luo D, Wu H, et al
    Altered gut microbiota is associated with different immunologic responses to antiretroviral therapy in HIV-infected men who have sex with men.
    J Med Virol. 2023 Mar 15. doi: 10.1002/jmv.28674.
    PubMed     Abstract available
    
    
    
88. PISATURO M, Alessio L, Starace M, Macera M, et al
    CHARACTERIZATION OF HEPATITIS VIRUS CO-INFECTIONS IN A COHORT OF IMMIGRANTS LIVING IN SOUTHERN ITALY.
    J Med Virol. 2023 Mar 10. doi: 10.1002/jmv.28665.
    PubMed     Abstract available
    
    
    
89. SAGHAZADEH A, Rezaei N
    Inborn Errors of Immunity and Worries During the Monkeypox Outbreak.
    J Med Virol. 2023 Mar 8. doi: 10.1002/jmv.28644.
    PubMed     Abstract available
    
    
    
90. CORMA-GOMEZ A, Fernandez-Fuertes M, Vinuela L, Dominguez C, et al
    Reduced neutralizing antibody response to SARS-CoV-2 vaccine booster dose in people living with HIV with severe immunosuppression.
    J Med Virol. 2023 Mar 6. doi: 10.1002/jmv.28602.
    PubMed     Abstract available
    
    
    February 2023
91. WANG T, Zheng L, Zhao Q, Yao Y, et al
    Parainfluenza virus 5 is a next-generation vaccine vector for human infectious pathogens.
    J Med Virol. 2023 Feb 27. doi: 10.1002/jmv.28622.
    PubMed     Abstract available
    
    
    
92. RWIBASIRA GN, Dzinamarira T, Remera E, Malamba SS, et al
    Engagement in HIV continuum of care: another step needed to close the gap towards UNAIDS 90-90-90 targets among younger men in Rwanda.
    J Med Virol. 2023 Feb 24. doi: 10.1002/jmv.28619.
    PubMed     Abstract available
    
    
    
93. HARFOUCHE M, Alareeki A, Osman AMM, Alaama AS, et al
    Epidemiology of herpes simplex virus type 2 in the Middle East and North Africa: Systematic review, meta-analyses, and meta-regressions.
    J Med Virol. 2023 Feb 23. doi: 10.1002/jmv.28603.
    PubMed     Abstract available
    
    
    
94. LI Y, Peng X, Fu L, Wang B, et al
    Monkeypox awareness and low vaccination hesitancy among men who have sex with men in China.
    J Med Virol. 2023 Feb 14. doi: 10.1002/jmv.28567.
    PubMed     Abstract available
    
    
    
95. RZYMSKI P, Szuster-Ciesielska A, Dzieciatkowski T, Gwenzi W, et al
    mRNA vaccines: The future of prevention of viral infections?
    J Med Virol. 2023 Feb 10. doi: 10.1002/jmv.28572.
    PubMed     Abstract available
    
    
    
96. CICCARESE G, Di Biagio A, Bruzzone B, Guadagno A, et al
    Monkeypox outbreak in Genoa, Italy: clinical, laboratory, histopathologic features, management and outcome of the infected patients.
    J Med Virol. 2023 Feb 9. doi: 10.1002/jmv.28560.
    PubMed     Abstract available
    
    
    
97. LIU Y, Li Z, Lu X, Kuang YQ, et al
    Dysregulation of memory B cells and circulating T follicular helper cells is a predictor of poor immune recovery in HIV-infected patients on antiretroviral therapy.
    J Med Virol. 2023 Feb 8. doi: 10.1002/jmv.28559.
    PubMed     Abstract available
    
    
    
98. NOT A, Saludes V, Galvez M, Miralpeix A, et al
    Usefulness of dried blood spot samples for monitoring hepatitis C treatment outcome and reinfection among people who inject drugs in a test-and-treat program.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28544.
    PubMed     Abstract available
    
    
    
99. TORRE-TARAZONA E, Gonzalez-Robles A, Cascajero A, Jimenez P, et al
    Treatment with integrase inhibitors alters SARS-CoV-2 neutralization levels measured with HIV-based pseudotypes in people living with HIV.
    J Med Virol. 2023 Feb 2. doi: 10.1002/jmv.28543.
    PubMed     Abstract available
    
    
    January 2023
100. FERRE VM, Bitty-Anderson AM, Peytavin G, Le MP, et al
     Pharmaco-virological algorithm to target risk of drug resistance among a population of HIV-infected key populations in Togo.
     J Med Virol. 2023 Jan 27. doi: 10.1002/jmv.28535.
     PubMed     Abstract available
     
     
     
101. PAN D, Nazareth J, Sze S, Martin CA, et al
     Transmission of Mpox: A narrative review of environmental, viral, host and population factors in relation to the 2022 international outbreak.
     J Med Virol. 2023 Jan 27. doi: 10.1002/jmv.28534.
     PubMed     Abstract available
     
     
     
102. ZHAO Y, Du J, Li Z, Wu Y, et al
     It Is Time to Improve the Acceptance of COVID-19 Vaccines Among People with Chronic Diseases: A Systematic Review and Meta-analysis.
     J Med Virol. 2023 Jan 19. doi: 10.1002/jmv.28509.
     PubMed     Abstract available
     
     
     December 2022
103. SRICHAWLA BS, Garcia-Dominguez MA, Zia S
     Secondary Complications and Management Strategies in Human Monkeypox: A Case Series.
     J Med Virol. 2022 Dec 30. doi: 10.1002/jmv.28449.
     PubMed     Abstract available
     
     
     
104. ZHAN H, Gao H, Liu Y, Zhang X, et al
     Booster shot of inactivated SARS-CoV-2 vaccine induces potent immune responses in people living with HIV.
     J Med Virol. 2022 Dec 26. doi: 10.1002/jmv.28428.
     PubMed     Abstract available
     
     
     
105. SANTINELLI L, Rossi G, Gioacchini G, Verin R, et al
     The crosstalk between gut barrier impairment, mitochondrial dysfunction and microbiota alterations in people living with HIV.
     J Med Virol. 2022 Dec 14. doi: 10.1002/jmv.28402.
     PubMed     Abstract available
     
     
     
106. GU L, Lin E, Liu S, Yang N, et al
     Efficacy of Immunotherapy with Combination of Cryotherapy and Topical Imiquimod for Treatment of Kaposi Sarcoma.
     J Med Virol. 2022 Dec 12. doi: 10.1002/jmv.28396.
     PubMed     Abstract available
     
     
     
107. PIRKL M, Buch J, Devaux C, Bohm M, et al
     Analysis of mutational history of multi-drug resistant genotypes with a mutagenetic tree model.
     J Med Virol. 2022 Dec 9. doi: 10.1002/jmv.28389.
     PubMed     Abstract available
     
     
     November 2022
108. DU M, Wang R, Yuan J, Lv X, et al
     Trends and disparities in 44 national notifiable infectious diseases in China: an analysis of national surveillance data from 2010 to 2019.
     J Med Virol. 2022 Nov 28. doi: 10.1002/jmv.28353.
     PubMed     Abstract available
     
     
     
109. ALBERTON F, Nozza S, Raccagni AR, Galli L, et al
     The Propensity for Long-Acting Cabotegravir and Rilpivirine Every Two Months Among HIV-Infected People Eligible for Treatment.
     J Med Virol. 2022 Nov 22. doi: 10.1002/jmv.28330.
     PubMed     Abstract available
     
     
     
110. BABATUNDE AO, Akin-Ajani OD, Abdullateef RO, Togunwa TO, et al
     Review of Antiretroviral therapy (ART) coverage in 10 highest-burden HIV countries in Africa: 2015-2020.
     J Med Virol. 2022 Nov 17. doi: 10.1002/jmv.28320.
     PubMed     Abstract available
     
     
     
111. SCHLESINGER M, McDonald C, Ahuja A, Canete CA, et al
     GLUCOSE AND MANNOSE ANALOGS INHIBIT KSHV REPLICATION BY BLOCKING N-GLYCOSYLATION AND INDUCING THE UNFOLDED PROTEIN RESPONSE.
     J Med Virol. 2022 Nov 15. doi: 10.1002/jmv.28314.
     PubMed     Abstract available
     
     
     
112. LOU M, Huang D, Zhou Z, Shi X, et al
     DNA virus oncoprotein HPV18 E7 selectively antagonizes cGAS-STING-triggered innate immune activation.
     J Med Virol. 2022 Nov 15. doi: 10.1002/jmv.28310.
     PubMed     Abstract available
     
     
     
113. CHU Q, Zhang X, Lan J, Zhang Q, et al
     Prevalence and Factors Associated with Late Diagnosis among Older Adults Living with HIV in Liuzhou, China: 2010-2020.
     J Med Virol. 2022 Nov 8. doi: 10.1002/jmv.28288.
     PubMed     Abstract available
     
     
     October 2022
114. ZHANG B, Liu JB, Zhou L, Wang X, et al
     Cytosolic DNA Sensors Activation Inhibits HIV Infection of Macrophages.
     J Med Virol. 2022 Oct 26. doi: 10.1002/jmv.28253.
     PubMed     Abstract available
     
     
     
115. LUO T, Pan Y, Liu Y, Zheng J, et al
     LANA regulates miR-155 /GATA3 signaling axis by enhancing c-Jun/c-Fos interaction to promote the proliferation and migration of KSHV-infected cells.
     J Med Virol. 2022 Oct 25. doi: 10.1002/jmv.28255.
     PubMed     Abstract available
     
     
     
116. FISH CS, Owiti P, Begnel ER, Itell HL, et al
     Comparison of nucleocapsid and spike antibody ELISAs for determining SARS-CoV-2 seropositivity in Kenyan women and infants.
     J Med Virol. 2022 Oct 17. doi: 10.1002/jmv.28221.
     PubMed     Abstract available
     
     
     
117. YUAN R, Zhang Y, Deng L, Yu X, et al
     A novel plasma proteomic-based model for predicting liver fibrosis in HIV/HBV co-infected adults.
     J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28222.
     PubMed     Abstract available
     
     
     
118. LI L, Cai W, Guo P, Hu F, et al
     Characteristics and clinical significance of plasma IL-18, sCD14 and sCD163 levels in patients with HIV-1 infection.
     J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28223.
     PubMed     Abstract available
     
     
     
119. SHEN S, Rui Y, Wang Y, Su J, et al
     SARS-CoV-2, HIV, HPV: convergent evolution of selective regulation of cGAS-STING signaling.
     J Med Virol. 2022 Oct 13. doi: 10.1002/jmv.28220.
     PubMed     Abstract available
     
     
     
120. FAN Q, Ma J, Li X, Jorba J, et al
     Molecular evolution and antigenic drift of type 3 iVDPVs excreted from a patient with immunodeficiency in Ningxia, China.
     J Med Virol. 2022 Oct 12. doi: 10.1002/jmv.28215.
     PubMed     Abstract available
     
     
     
121. RENGASAMY KR
     Will Monkeypox Outbreak mirror COVID-19 or AIDs?
     J Med Virol. 2022 Oct 10. doi: 10.1002/jmv.28202.
     PubMed     Abstract available
     
     
     
122. KIM MG, Gulholm T, Lennard K, Mirdad F, et al
     The impact of cerebrospinal fluid viral polymerase chain reaction testing on the management of adults with viral meningitis: A multi-center retrospective study.
     J Med Virol. 2022 Oct 7. doi: 10.1002/jmv.28198.
     PubMed     Abstract available
     
     
     
123. ZHANG F, Yang Z, Dai C, He Q, et al
     Efficacy of an accelerated vaccination schedule against hepatitis E virus infection in pregnant rabbits.
     J Med Virol. 2022 Oct 6. doi: 10.1002/jmv.28193.
     PubMed     Abstract available
     
     
     
124. SOLIS-LEAL A, May AM, Mohan M, Dufour JP, et al
     Duration of antiretroviral therapy impacts the degree of residual SIV infection in the gut in long-term non-progressing Chinese rhesus macaques.
     J Med Virol. 2022 Oct 1. doi: 10.1002/jmv.28185.
     PubMed     Abstract available
     
     
     September 2022
125. HERMANUSSEN L, Grewe I, Tang HT, Norz D, et al
     Tecovirimat therapy for severe monkeypox infection: Longitudinal assessment of viral titers and clinical response pattern - A first case-series experience.
     J Med Virol. 2022 Sep 30. doi: 10.1002/jmv.28181.
     PubMed     Abstract available
     
     
     
126. SHCHEMELEV AN, Boumbaly S, Ostankova YV, Zueva EB, et al
     Prevalence of drug resistant HIV-1 forms in patients without any history of ART in the Republic of Guinea.
     J Med Virol. 2022 Sep 29. doi: 10.1002/jmv.28184.
     PubMed     Abstract available
     
     
     
127. SERWIN K, Scheibe K, Horecki M, Aksak-Was B, et al
     Detection of Polish cases of highly virulent subtype B of HIV-1 originating in the Netherlands.
     J Med Virol. 2022 Sep 15. doi: 10.1002/jmv.28154.
     PubMed     Abstract available
     
     
     August 2022
128. GENG Y, Wang Y
     Stability and transmissibility of SARS-CoV-2 in the environment.
     J Med Virol. 2022 Aug 30. doi: 10.1002/jmv.28103.
     PubMed     Abstract available
     
     
     
129. GHALEKHANI N, Bokaie S, Eybpoosh S, Akbarein H, et al
     Reconstruction of molecular evolution of human influenza A H1N1/2009 virus in Iran and neighboring countries.
     J Med Virol. 2022 Aug 24. doi: 10.1002/jmv.28090.
     PubMed     Abstract available
     
     
     
130. KHELLAF L, Bouscarat F, Burrel S, Fidouh N, et al
     Novel mutations in antiviral multiresistant HSV-2 genital lesion: a case report.
     J Med Virol. 2022 Aug 16. doi: 10.1002/jmv.28070.
     PubMed     Abstract available
     
     
     
131. JIANG X, Sharma PP, Rathi B, Ji X, et al
     Discovery of novel 1,2,4-triazole phenylalanine derivatives targeting an unexplored region within the interprotomer pocket of the HIV capsid protein.
     J Med Virol. 2022 Aug 10. doi: 10.1002/jmv.28064.
     PubMed     Abstract available
     
     
     July 2022
132. RUPASINGHE D, Choi JY, Yunihastuti E, Kiertiburanakul S, et al
     Factors associated with high alanine aminotransferase (ALT) and cirrhosis in people living with HIV on combination antiretroviral treatment (cART) in the Asia-Pacific.
     J Med Virol. 2022 Jul 22. doi: 10.1002/jmv.28019.
     PubMed     Abstract available
     
     
     
133. LAN J, Li W, Yu R, Syed F, et al
     Cell-to-cell transmission of HIV-1 from provirus-activated cells to resting naive and memory human primary CD4 T cells is highly efficient and requires CD4 and F-actin but not chemokine receptors.
     J Med Virol. 2022 Jul 15. doi: 10.1002/jmv.28005.
     PubMed     Abstract available
     
     
     June 2022
134. ZHU K, Xu Q, Ma Y, Li P, et al
     Suboptimal Immune Recovery and Associated Factors Among People Living with HIV/AIDS on Second-line Antiretroviral Therapy in Central China: A Retrospective Cohort Study.
     J Med Virol. 2022 Jun 16. doi: 10.1002/jmv.27944.
     PubMed     Abstract available
     
     
     
135. AGUILAR G, Truong HM, Ovelar P, Samudio T, et al
     HIV Drug Resistance in Persons Initiating or Re-initiating First-line Antiretroviral Therapy in Paraguay: Results of a National Patient Survey.
     J Med Virol. 2022 Jun 14. doi: 10.1002/jmv.27933.
     PubMed     Abstract available
     
     
     
136. BRAGAZZI NL, Kong JD, Mahroum N, Tsigalou C, et al
     Epidemiological trends and clinical features of the ongoing monkeypox epidemic: a preliminary pooled data analysis and literature review.
     J Med Virol. 2022 Jun 12. doi: 10.1002/jmv.27931.
     PubMed     Abstract available
     
     
     
137. ASHURO AA, Zhang SC, Wang T, Chu QS, et al
     The Effect of protease inhibitors-based antiretroviral therapy on serum/plasma interleukin-6 levels among PLHIV: a systematic review and meta-analysis.
     J Med Virol. 2022 Jun 6. doi: 10.1002/jmv.27912.
     PubMed     Abstract available
     
     
     
138. SAIED AA, Nascimento MSL, Rangel AHDN, Skowron K, et al
     Transchromosomic bovines (TcB)-derived broadly neutralizing antibodies as potent biotherapeutics to counter important emerging viral pathogens with a special focus on SARS-CoV-2, MERS-CoV, Ebola, Zika, HIV-1 and Influenza A virus.
     J Med Virol. 2022 Jun 2. doi: 10.1002/jmv.27907.
     PubMed     Abstract available
     
     
     May 2022
139. BORGHETTI A, Farinacci D, Ciccullo A, Dusina A, et al
     Are we ready for long-acting? A feasibility evaluation of long-acting cabotegravir-rilpivirine in clinical practice.
     J Med Virol. 2022 May 31. doi: 10.1002/jmv.27890.
     PubMed     Abstract available
     
     
     
140. FLEISCHER B, Olum R, Nakwagala FN, Nassozi DR, et al
     Higher intensive care unit consultations for COVID-19 patients living with HIV compared to those without HIV coinfection in Uganda.
     J Med Virol. 2022 May 26. doi: 10.1002/jmv.27887.
     PubMed     Abstract available
     
     
     
141. CHU FL, Li C, Chen L, Dong B, et al
     Respiratory viruses among pediatric inpatients with acute lower respiratory tract infections in Jinan, China, 2016-2019.
     J Med Virol. 2022 May 20. doi: 10.1002/jmv.27875.
     PubMed     Abstract available
     
     
     
142. CAI S, Liao G, Yu T, Gao Q, et al
     Immunogenicity and safety of an inactivated SARS-CoV-2 vaccine in people living with HIV: A cross-sectional study.
     J Med Virol. 2022 May 18. doi: 10.1002/jmv.27872.
     PubMed     Abstract available
     
     
     
143. MALONGA GA, Dienta S, Traore FT, Maiga Z, et al
     Human Herpesvirus 8 seroprevalence among blood donors in Mali.
     J Med Virol. 2022 May 11. doi: 10.1002/jmv.27850.
     PubMed     Abstract available
     
     
     
144. LALLOGO TD, Djigma FW, Sorgho PA, Martinson JJ, et al
     KIR2DL5B and HLA DRB1*12 alleles seems to be associated with protection against HIV-1 in serodiscordant couples in Burkina Faso.
     J Med Virol. 2022 May 2. doi: 10.1002/jmv.27821.
     PubMed     Abstract available
     
     
     April 2022
145. LI Y, Wang X, Jin J, Ma Z, et al
     T cell responses to SARS-CoV-2 Omicron spike epitopes with mutations after the third booster dose of an inactivated vaccine.
     J Med Virol. 2022 Apr 26. doi: 10.1002/jmv.27814.
     PubMed     Abstract available
     
     
     
146. YU H, Wu H, Subapriya R, Kaur A, et al
     Single-Center Experience on Progressive Multifocal Leukoencephalopathy (PML) cases, neuroimaging relevance, and management at West Virginia University (WVU).
     J Med Virol. 2022 Apr 21. doi: 10.1002/jmv.27804.
     PubMed     Abstract available
     
     
     
147. ZHUANG K, Zhang Y, Mo P, Deng L, et al
     Plasma proteomic analysis reveals altered protein abundances in HIV-infected patients with or without Non-Hodgkin Lymphoma.
     J Med Virol. 2022 Apr 12. doi: 10.1002/jmv.27775.
     PubMed     Abstract available
     
     
     
148. MEHRAEEN E, SeyedAlinaghi S, Karimi A
     The Post-Omicron Situation: The End of the Pandemic or a Bigger Challenge?
     J Med Virol. 2022 Apr 6. doi: 10.1002/jmv.27765.
     PubMed     Abstract available
     
     
     March 2022
149. FIORE BD, Andrea V, Giuseppe P, Yagai B, et al
     Early versus delayed antiretroviral therapy based on genotypic resistance test: Results from a large retrospective cohort study.
     J Med Virol. 2022 Mar 31. doi: 10.1002/jmv.27754.
     PubMed     Abstract available
     
     
     
150. HUANG J, Wu H, Lin S, Lu L, et al
     Spatial-temporal analysis of HIV/AIDS and syphilis in mainland China from 2007 to 2017.
     J Med Virol. 2022 Mar 16. doi: 10.1002/jmv.27725.
     PubMed     Abstract available
     
     
     
151. WILLIAMS ME, Ruhanya V, Paul RH, Ipser JC, et al
     An investigation of the HIV Tat C31S and R57S mutation on peripheral immune marker levels in South African participants: A pilot study.
     J Med Virol. 2022 Mar 13. doi: 10.1002/jmv.27720.
     PubMed    
     
     
     
152. GIOVANETTI M, Farcomeni S, Sernicola L, Virtuoso S, et al
     Analysis of HIV-1 integrase genotypes and polymorphisms among integrase inhibitors-based antiretroviral treatment naive patients in South Sudan.
     J Med Virol. 2022 Mar 11. doi: 10.1002/jmv.27713.
     PubMed     Abstract available
     
     
     
153. SU B, Kong D, Yang X, Zhang T, et al
     Mucosal-associated invariant T cells: a cryptic coordinator in HIV-infected immune reconstitution.
     J Med Virol. 2022 Mar 3. doi: 10.1002/jmv.27696.
     PubMed     Abstract available
     
     
     February 2022
154. MARAIS G, Naidoo M, McMullen K, Stanley A, et al
     Varicella-zoster virus reactivation is frequently detected in HIV-infected individuals presenting with stroke.
     J Med Virol. 2022 Feb 8. doi: 10.1002/jmv.27651.
     PubMed     Abstract available
     
     
     
155. SHAHZAD M, Chen H, Akhtar T, Rafi A, et al
     Human Immunodeficiency Virus: The potential of medicinal plants as anti-retroviral therapy.
     J Med Virol. 2022 Feb 6. doi: 10.1002/jmv.27648.
     PubMed     Abstract available
     
     
     
156. MILANO E, Ricciardi A, Casciaro R, Pallara E, et al
     Immunogenicity and safety of the BNT162b2 COVID-19 mRNA vaccine in PLWH: a monocentric study in Bari, Italy.
     J Med Virol. 2022 Feb 1. doi: 10.1002/jmv.27629.
     PubMed     Abstract available
     
     
     January 2022
157. COUTLEE F, de Pokomandy A, Burchell AN, El-Zein M, et al
     Human papillomavirus genotype concordance between Anyplex II HPV28 and linear array HPV genotyping test in anogenital samples.
     J Med Virol. 2022 Jan 20. doi: 10.1002/jmv.27605.
     PubMed     Abstract available
     
     
     
158. ZHANG X, Fang Q, Zhu S, Wu X, et al
     Environmental risk factors and genetic markers of Kaposi's sarcoma-associated herpesvirus infection among Uygur population in Xinjiang, China.
     J Med Virol. 2022 Jan 18. doi: 10.1002/jmv.27600.
     PubMed     Abstract available
     
     
     
159. LI T, Cui Z, Jia Y, Liang Z, et al
     Aggregation of high-frequency RBD mutations of SARS-CoV-2 with three VOCs did not cause significant antigenic drift.
     J Med Virol. 2022 Jan 14. doi: 10.1002/jmv.27596.
     PubMed     Abstract available
     
     
     
160. KURY CMH, Guimaraes GR, Leandro CG, Fernandes LA, et al
     Associations of human papillomavirus (HPV) genotypes and related risk factors in a cohort of women living with HIV in a Brazilian countryside city.
     J Med Virol. 2022 Jan 9. doi: 10.1002/jmv.27582.
     PubMed     Abstract available
     
     
     
161. AKEKAWATCHAI C, Phuegsilp C, Changsri K, Soimanee T, et al
     Distribution of +874T/A IFN-gamma and -509C/T TGF-beta1 Single Nucleotide Polymorphisms in Human Immunodeficiency Virus-infected Thais.
     J Med Virol. 2022 Jan 4. doi: 10.1002/jmv.27567.
     PubMed     Abstract available
     
     
     
162. MOUSAVI SH, Qaderi S, Ahmadi A, Arman SI, et al
     The daunting task of fighting HIV in Afghanistan: Current evidence and future recommendationsThe daunting task of fighting HIV in Afghanistan: Current evidence and future recommendations.
     J Med Virol. 2022 Jan 3. doi: 10.1002/jmv.27566.
     PubMed     Abstract available
     
     
     
163. ADACHI E, Saito M, Nagai H, Ikeuchi K, et al
     Transient depletion of T cells during COVID-19 and seasonal influenza in people living with HIV.
     J Med Virol. 2022 Jan 2. doi: 10.1002/jmv.27543.
     PubMed     Abstract available
     
     
     December 2021
164. DENG H, Feng Q, Wu Y, Lin H, et al
     Immune response to hepatitis B vaccination in human immunodeficiency virus-positive patients in China: A 2-year retrospective study.
     J Med Virol. 2021 Dec 14. doi: 10.1002/jmv.27523.
     PubMed     Abstract available
     
     
     
165. BORSETTI A, Scarpa F, Maruotti A, Divino F, et al
     The unresolved question on COVID-19 virus origin: The three cards game?
     J Med Virol. 2021 Dec 12. doi: 10.1002/jmv.27519.
     PubMed     Abstract available
     
     
     October 2021
166. CHAVAN VR, Ahir S, Kerkar S, Ansari Z, et al
     Th1 cytokine gene polymorphism and the corresponding plasma cytokine levels: A comparative study in HIV-1 positive and exposed uninfected infants.
     J Med Virol. 2021 Oct 26. doi: 10.1002/jmv.27408.
     PubMed     Abstract available
     
     
     
167. MATSUDA EM, Ahagon CM, Coelho LPO, Campos IB, et al
     A simple algorithm for selecting cases to investigate acute and early HIV infections in low- and middle-income countries.
     J Med Virol. 2021 Oct 14. doi: 10.1002/jmv.27398.
     PubMed     Abstract available
     
     
     
168. RAHMAN S, Sarker MS, Aralaguppe SG, Sarwar G, et al
     Drug resistance pattern among ART-naive clients attending an HIV testing and counseling center in Dhaka, Bangladesh.
     J Med Virol. 2021 Oct 12. doi: 10.1002/jmv.27387.
     PubMed     Abstract available
     
     
     August 2021
169. ZHOU R, Liu L, Wang Y
     Viral Proteins Recognized by Different TLRs.
     J Med Virol. 2021 Aug 10. doi: 10.1002/jmv.27265.
     PubMed     Abstract available
     
     
     June 2021
170. SILVA DMD, Goncales JP, Silva Junior JVJ, Lopes TRR, et al
     Evaluation of IL-2, IL-4, IL-6, IL-10, TNF-alpha, and IFN-gamma cytokines in HIV/HHV-8 coinfection.
     J Med Virol. 2021;93:4033-4037.
     PubMed     Abstract available
     
     
     
171. LU J, Jia J, Zhang J, Liu X, et al
     HIV p17 enhances T cell proliferation by suppressing autophagy through the p17-OLA1-GSK3beta axis under nutrient starvation.
     J Med Virol. 2021;93:3607-3620.
     PubMed     Abstract available
     
     
     
172. DAI L, Jung BG, Chen J, Samten B, et al
     The potential impacts of early secreted antigenic target of 6 kDa of Mycobacterium tuberculosis on KSHV-infected cells.
     J Med Virol. 2021;93:4028-4032.
     PubMed     Abstract available
     
     
     
173. DA SILVA PRATES G, Malta FM, de Toledo Goncalves F, Monteiro MA, et al
     AIDS incidence and survival in a hospital-based cohort of HIV-positive patients from Sao Paulo, Brazil: The role of IFN-lambda4 polymorphisms.
     J Med Virol. 2021;93:3601-3606.
     PubMed     Abstract available
     
     

Thank you for your interest in scientific medicine.

AMEDEO HIV Infection is free of charge.